AlphaFold predicted structure
GAMT · Q14353

Mean pLDDT
96.4/ 100
Very high
236 residues
Confidence breakdown
- Very high(≥ 90)97%
- Confident(70–90)1%
- Low(50–70)1%
- Very low(< 50)2%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
guanidinoacetate N-methyltransferase
Annotations refreshed 1 month ago.
Diagnostic Grade (Green)
DDG2P
BIALLELIC, autosomal or pseudoautosomalEarly onset or syndromic epilepsy
BIALLELIC, autosomal or pseudoautosomalIntellectual disability
BIALLELIC, autosomal or pseudoautosomalLikely inborn error of metabolism
BIALLELIC, autosomal or pseudoautosomalUndiagnosed metabolic disorders
BIALLELIC, autosomal or pseudoautosomalAdult onset dystonia, chorea or related movement disorder
Adult onset neurodegenerative disorder
UnknownChildhood onset dystonia, chorea or related movement disorder
BIALLELIC, autosomal or pseudoautosomal+2 more panels — install the extension to see the full list inline on any page.
guanidinoacetate methyltransferase deficiency
cerebral creatine deficiency syndrome
hereditary disease
Intellectual disability
Seizure
Abnormality of the nervous system
Parkinson disease
late-onset Parkinson disease
Hereditary late-onset Parkinson disease
metabolic syndrome
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Guanidinoacetate N-methyltransferase
Converts guanidinoacetate to creatine, using S-adenosylmethionine as the methyl donor (PubMed:24415674, PubMed:26003046, PubMed:26319512). Important in nervous system development (PubMed:24415674)
GAMT · Q14353

Mean pLDDT
96.4/ 100
Very high
236 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0